Amneal’s $2 Million Parkinson’s Patient Copay Support Program
Amneal Pharmaceuticals donated $2 million to multiple patient assistance foundations to cover copayments, coinsurance and deductibles for FDA-approved Parkinson’s disease medications. This contribution brings the company’s total Parkinson’s support to $3.5 million over the past two years.
1. Donation Allocation
Amneal allocated $2 million to several patient assistance foundations in April 2026, targeting copayments, coinsurance and deductibles for FDA-approved Parkinson’s disease therapies to lower out-of-pocket expenses for eligible patients.
2. Philanthropic Track Record
Over the past two years, the company has contributed a total of $3.5 million to Parkinson’s support initiatives, reflecting a sustained investment in patient access programs and advocacy engagement.
3. Patient Cost Relief
Funds will help manage varying levels of patient cost sharing, ensuring individuals living with Parkinson’s disease can afford essential medications throughout different stages of treatment.
4. Community Outreach Efforts
Amneal also provides educational resources, including Spanish-language materials, and participates in nationwide advocacy events to raise disease awareness and foster community support alongside these financial contributions.